Palisade Bio Receives Canadian Patent Covering Composition Of Lead Program In Development, LB1148
Palisade Bio, Inc. (NASDAQ:PALI) (the "Company"), a biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced that the Canadian Intellectual